相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Gastrosplenic Fistula From Hodgkin's Lymphoma
Carolyn D. Seib et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Colorectal Hepatic Metastases: Adjuvant Chemotherapy and Survival
David J. Gallagher et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss
Blaise Clarke et al.
MODERN PATHOLOGY (2009)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Cancer statistics, 2008
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2008)
Is it time to stratify for BRCA mutation status in therapeutic trials in ovarian cancer?
Noah D. Kauff
JOURNAL OF CLINICAL ONCOLOGY (2008)
BRCAness Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated With BRCA1 and BRCA2 Mutations
David S. P. Tan et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: The national Israeli study of ovarian cancer
Angela Chetrit et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab
W. De Roock et al.
ANNALS OF ONCOLOGY (2008)
Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group Study
William E. Winter et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
PIEPOC: A new prognostic index for advanced epithelial ovarian cancer - Japan Multinational Trial Organization OC01-01
Satoshi Teramukai et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab
Shirin Khambata-Ford et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR)
Pauline Wimberger et al.
GYNECOLOGIC ONCOLOGY (2007)
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
F. Di Fiore et al.
BRITISH JOURNAL OF CANCER (2007)
Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer
T Walsh et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Intraperitoneal cisplatin and paclitaxel in ovarian cancer
DK Armstrong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases
T Pal et al.
CANCER (2005)
Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study
SM Eisenkop et al.
GYNECOLOGIC ONCOLOGY (2003)
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer
L Zhang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis
RE Bristow et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer
HA Risch et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
Clinicopathologic features of BRCA-linked and sporadic ovarian cancer
J Boyd et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
